BLOGS

It depends on whom you work for...Two important highlights:   1. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize - On April 01, 2026, FDA clarifies policies for compounders. The FDA stated that a compounded drug product is considered essentially a copy of a commercially available drug product if · The compounded drug product contains the same APIs as two or more commercially available drug product

Receiving a warning letter (WL) from the Food and Drug Administration (FDA) can be a critical moment for any company in the pharmaceutical, food, or medical device industries. These letters highlight serious regulatory violations and demand prompt corrective actions. Successfully addressing these concerns is essential not only to avoid legal consequences but also to maintain trust with consumers and regulators. This post explores practical strategies to navigate remediation e

When the FDA completes a Current Good Manufacturing Practice (CGMP) inspection of a drug manufacturing facility whether it's CDER, CBER, and/or CVM products, it often issues a Form 483 to document any observed deviations from regulatory requirements. These observations can range from minor documentation issues to serious manufacturing flaws. How a company responds to these observations can significantly impact its regulatory standing and business operations. This post explor